Updated: Oct 20
Medically reviewed by ChinaCureLink Team
Table of Content
Introduction
Patients researching hemophilia A may encounter AAV gene therapy as an emerging treatment approach. In China, this therapy is currently available through a translational application pathway in the Boao Lecheng Pilot Zone. This guide explains what the treatment is, how hemophilia A gene therapy China access works, who may be considered, its estimated cost, and what international patients should know before pursuing it.
Key Takeaways |
|
What Is AAV Gene Therapy for Hemophilia A?
AAV gene therapy uses a modified, non-pathogenic adeno-associated virus (AAV) vector to deliver a functional FVIII gene into liver and other cells. The aim is for those cells to produce factor VIII internally rather than relying solely on repeated replacement-factor infusions.
The treatment is administered by intravenous infusion and is designed as a single administration rather than a series of repeated injections. The treatment approach is intended to support longer-term endogenous production of clotting factor, although the duration and consistency of expression are individual clinical considerations.
Clinical application of AAV gene therapy remains an area requiring medical evaluation. Its availability through a pilot-zone pathway should not be interpreted as proof of a particular clinical outcome.
Hemophilia A Gene Therapy China: Availability and Access
AAV gene therapy for hemophilia A is available through a translational application pathway in the Boao Lecheng Pilot Zone in Hainan. The treatment has a low-risk regulatory classification and a registration year of 2025.
For international patients researching hemophilia A gene therapy China, the key distinction is that this is a specific pilot-zone access pathway rather than nationwide approval for routine use throughout China. Patients therefore need to work with the designated hospital and undergo individual medical assessment before treatment can be considered.
The pathway does not constitute a clinical trial unless the treating institution separately identifies a particular treatment as such.
Where Is Hemophilia A Gene Therapy Offered in China?
The treatment is offered at Hainan Haikong Le City Hospital (West China Le City Hospital of Sichuan University) within the Boao Lecheng Pilot Zone.
Technical support is provided by Suzhou Huayi Lejian Biotechnology Co., Ltd.
The treatment modality is AAV-based gene therapy administered through intravenous infusion.
Who May Be Eligible for Hemophilia A Gene Therapy?
Eligibility begins with confirmed hemophilia A caused by congenital FVIII deficiency.
Suitability depends on several individual indicators, including:
Age
Liver function
Presence of AAV neutralizing antibodies
Previous medication history
Presence of inhibitors
These factors are assessed comprehensively by the attending physician. Patients should not determine their own eligibility based on these criteria alone.
Final eligibility is determined by the treating medical team after a face-to-face consultation and review of the patient's medical records.
How Much Does Hemophilia A Gene Therapy Cost in China?
The estimated cost is ¥680,000 (approximately US$101,200) per session. The USD figure uses a reference exchange rate of about 6.72 CNY per US dollar and is intended only as a currency reference; exchange rates can change.
The quoted treatment price does not necessarily include consultation, diagnostic testing, hospitalization, translation or coordination services, or international travel. Patients should confirm the full scope of costs and final pricing directly with the hospital before making travel arrangements.
Why International Patients May Consider Hemophilia A Gene Therapy China
For some international patients with hemophilia A, access to an AAV-based gene therapy through a designated Chinese pilot-zone pathway may provide another treatment option to discuss with specialists.
The potential relevance of this approach is different from conventional factor replacement because the therapy is designed to introduce a functional FVIII gene and support endogenous factor production. However, individual suitability depends on medical factors such as liver function, AAV neutralizing antibodies, inhibitors, age, and treatment history.
Patients should evaluate the treatment with qualified physicians rather than assuming that pilot-zone availability means it is appropriate for every person with hemophilia A.
How ChinaCureLink Can Help Patients Access This Treatment
We help international patients explore available treatment options and facilitate communication with appropriate medical specialists. Patients should discuss potential benefits, risks, eligibility, and alternatives directly with qualified physicians. ChinaCureLink does not represent or endorse the treatment technology, manufacturer, or hospital.
Case review: We collect relevant medical history and hemophilia A-management records to help determine whether a case is appropriate for physician review.
Hospital coordination: We help connect patients with the treating team at Hainan Haikong Le City Hospital (West China Le City Hospital of Sichuan University) in China for an initial assessment.
Online consultation before travel: Patients can discuss potential eligibility, the procedure, and expected next steps with the medical team remotely before committing to international travel.
Coordination support: Depending on the case, this can include translation assistance, appointment scheduling, and logistics coordination.
Considering AAV Gene Therapy for Hemophilia A in China?
Before planning travel, speak with a qualified specialist to determine whether the treatment is appropriate for your condition and whether you meet the medical eligibility requirements. ChinaCureLink can help international patients arrange a specialist review and explore the treatment pathway in China. [Request a Medical Review / Speak With a Specialist]
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
Is hemophilia A gene therapy available in China?
Yes. AAV gene therapy for hemophilia A is available through a translational application pathway in the Boao Lecheng Pilot Zone at Hainan Haikong Le City Hospital. This pathway does not mean nationwide approval.
How much does hemophilia A gene therapy cost in China?
The estimated cost is approximately US$101,200 per session. Patients should confirm final pricing and exactly what is included directly with the hospital.
Who may qualify for hemophilia A gene therapy?
Individuals with confirmed hemophilia A and congenital FVIII deficiency may be considered. Age, liver function, AAV neutralizing antibodies, previous medication history, and inhibitors are among the factors assessed by the attending physician.
Can international patients explore AAV gene therapy in China?
Yes. International patients can seek an assessment through the designated hospital, subject to medical eligibility and the requirements of the Boao Lecheng access pathway.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
